Search
- Page Path
- HOME > Search
- Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
- Lucas Pereira Jorge de Medeiros, Mario Barreto Correa Lima, Marcia Maria Amêndola Pires, Alessandra Mendonça Almeida Maciel, Renata Barboza Vianna Medeiros, Mariana Dermínio Donadel, Isabela Martins Becattini Pereira, Fábio Marchon Leão, Luiz Eduardo Amorim Correa Lima Pires, Helio Rzetelna, Carlos Eduardo Brandão-Mello
- Osong Public Health Res Perspect. 2018;9(2):50-58. Published online April 30, 2018
- DOI: https://doi.org/10.24171/j.phrp.2018.9.2.03
- 5,714 View
- 42 Download
- 4 Crossref
-
Abstract
PDF Objectives To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV).
Methods 4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).
Results Of the global sample of 55 patients included in this study; SOF + DCV (
n = 10); SOF + DCV + RBV (n = 29); SOF + SMV (n = 16) all had a statistically significant improvement in SF-36, CLDQ and FACIT-F scores during and post-treatment. No statistically significant differences in the PRO questionnaire values were observed between the distinct treatment regimens. The SOF and SMV patient groups presented higher mean PRO variations during and post-treatment, compared to the other groups: SF-36 functional capacity (16.1); SF-36 mental health (21.4); CLDQ activity (1.8); CLDQ emotional function (1.2); FACIT-F physical well-being (8.0); Total FACIT-F (21.6).Conclusion Treatment with SOF + DCV, with or without RBV, results in an improved PRO similar to treatment with SOF + SMV in chronic hepatitis C patients.
-
Citations
Citations to this article as recorded by
- Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
Olav Dalgard, Alain H. Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L. Altice, Brian Conway, Edward J. Gane, Anne F. Luetkemeyer, Cheng-Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M. Kelly, Barbara A. Haber, Heather Platt, Amy
Journal of Addictive Diseases.2023; 41(3): 213. CrossRef - Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus
Evy Yunihastuti, Fhadilla Amelia, Arini Ika Hapsari, Bramantya Wicaksana, Veritea Natali, Alvina Widhani, Andri Sanityoso Sulaiman, Teguh Harjono Karjadi
Health and Quality of Life Outcomes.2021;[Epub] CrossRef - Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free
Raíssa Neves Fagundes, Lincoln Eduardo Villela Vieira de Castro Ferreira, Fábio Heleno de Lima Pace, Yury E. Khudyakov
PLOS ONE.2020; 15(8): e0237005. CrossRef - Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination
Juan Li, Dong-Bo Wu, Wei Jiang, Xue-Bin Chen, Gui-Bao Xiao, Yong-Hong Wang, Meng-Lan Wang, Ya-Chao Tao, En-Qiang Chen
Medicine.2020; 99(43): e22726. CrossRef
- Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
First
Prev
